PROT Stock Overview
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Proteonomix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.00001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PROT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how PROT performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PROT performed against the US Market.
Price Volatility
| PROT volatility | |
|---|---|
| PROT Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PROT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PROT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | Michael Cohen | www.proteonomix.com |
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company’s products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles.
Proteonomix, Inc. Fundamentals Summary
| PROT fundamental statistics | |
|---|---|
| Market cap | US$7.00 |
| Earnings (TTM) | -US$672.05k |
| Revenue (TTM) | US$26.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs PROT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROT income statement (TTM) | |
|---|---|
| Revenue | US$26.00k |
| Cost of Revenue | -US$513.00 |
| Gross Profit | US$26.52k |
| Other Expenses | US$698.57k |
| Earnings | -US$672.05k |
Last Reported Earnings
Jun 30, 2012
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PROT perform over the long term?
See historical performance and comparison